<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004231</url>
  </required_header>
  <id_info>
    <org_study_id>NU 96H3</org_study_id>
    <secondary_id>NU-96H3</secondary_id>
    <secondary_id>NCI-G99-1659</secondary_id>
    <nct_id>NCT00004231</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma</brief_title>
  <official_title>Phase II Study of Multimodality Therapy in Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow&#xD;
      transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more&#xD;
      cancer cells. Biological therapies use different ways to stimulate the immune system and stop&#xD;
      cancer cells from growing.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by&#xD;
      bone marrow or peripheral stem cell transplantation and/or biological therapy in treating&#xD;
      patients who have stage III, stage IV, or recurrent mantle cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxicities of combination chemotherapy followed by allogeneic or&#xD;
           autologous bone marrow transplantation or peripheral blood stem cell transplantation&#xD;
           and/or interferon and interleukin therapy in patients with refractory or stage III or IV&#xD;
           mantle cell lymphoma.&#xD;
&#xD;
        -  Determine the complete response rate in these patients after these treatments.&#xD;
&#xD;
        -  Evaluate the prognostic factors in this patient population.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive induction chemotherapy consisting of cyclophosphamide IV, doxorubicin IV,&#xD;
      and teniposide IV over 2 hours on day 1, oral prednisone on days 1-5, vincristine IV and&#xD;
      methotrexate IV over 2 hours on day 21, cytarabine IV over 2 hours every 12 hours for a total&#xD;
      of 2 doses on day 22, and oral leucovorin calcium every 6 hours beginning on day 22 and&#xD;
      continuing until methotrexate levels recover. Treatment repeats every 42 days for 2 courses.&#xD;
      Patients achieving complete response or partial response receive an additional course of&#xD;
      induction therapy. Patients achieving maximal response following 2 courses of induction&#xD;
      chemotherapy undergo transplantation.&#xD;
&#xD;
      Patients under 50 years with an HLA matched donor undergo allogeneic bone marrow&#xD;
      transplantation (BMT). Patients receive busulfan IV every 6 hours for a total of 14 doses&#xD;
      beginning on day -8 and continuing for 3.5 days. At 24 hours following the last dose of&#xD;
      busulfan, patients receive cyclophosphamide IV over 2 hours daily for 2 days. Patients&#xD;
      receive allogeneic bone marrow infusion on day 0.&#xD;
&#xD;
      Patients under 50 years with no HLA matched donor or patients 50-65 years old undergo&#xD;
      autologous bone marrow or peripheral blood stem cell (PBSC) transplantation. Patients undergo&#xD;
      PBSC mobilization following completion of cyclophosphamide, doxorubicin, and teniposide&#xD;
      portion of induction therapy of course 3. Patients receive cytokines subcutaneously (SQ)&#xD;
      beginning 2 days following chemotherapy and continuing through PBSC collection. If&#xD;
      insufficient stem cells are collected and there is negative bone marrow involvement, patients&#xD;
      undergo bone marrow harvest. Patients receive a conditioning regimen consisting of busulfan&#xD;
      and cyclophosphamide as for allogeneic BMT. Patients receive autologous bone marrow or PBSC&#xD;
      infusion on day 0 and filgrastim (G-CSF) SQ beginning on day 0 and continuing until blood&#xD;
      counts recover. Following blood count recovery, patients receive maintenance therapy&#xD;
      consisting of interferon alfa SQ and interleukin-2 SQ daily over 5 consecutive days for 4&#xD;
      weeks. Treatment repeats every 8 weeks for 2 courses.&#xD;
&#xD;
      Patients 65 years or older achieving complete or partial response to induction chemotherapy&#xD;
      receive maintenance therapy as for autologous BMT. Patients achieving partial response may&#xD;
      receive an additional 4th course of induction therapy prior to maintenance therapy.&#xD;
&#xD;
      Patients are followed at 30 days post transplant, every 3 months for 1 year, and then at&#xD;
      least every 6 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-48 patients will be accrued for this study over 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teniposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage III, IV, or recurrent mantle cell lymphoma&#xD;
&#xD;
               -  CD5 positive OR&#xD;
&#xD;
               -  Evidence of bcl-1 oncogene overexpression&#xD;
&#xD;
          -  Measurable or evaluable disease with at least one of the following:&#xD;
&#xD;
               -  Clear cut radiographic findings&#xD;
&#xD;
               -  Clearly defined bidimensional defect or mass at least 2 cm in diameter on&#xD;
                  radionuclide or CT scan&#xD;
&#xD;
               -  Enlarged spleen extending at least 2 cm below costal margin with lymphomatous&#xD;
                  involvement only&#xD;
&#xD;
               -  Enlarged liver with proof of lymphoma by biopsy&#xD;
&#xD;
          -  CNS involvement allowed&#xD;
&#xD;
          -  Fully HLA matched donor for allogeneic transplantation&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-3&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 3.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No significant cardiac disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior malignancies except previously treated nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other medical problems that would preclude study&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior chemotherapy, including doxorubicin, allowed&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior steroids allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior radiotherapy allowed excluding the indicator lesions&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leo I. Gordon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Evens AM, Winter JN, Hou N, Nelson BP, Rademaker A, Patton D, Singhal S, Frankfurt O, Tallman MS, Rosen ST, Mehta J, Gordon LI. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol. 2008 Feb;140(4):385-93. doi: 10.1111/j.1365-2141.2007.06908.x. Epub 2007 Dec 19.</citation>
    <PMID>18162124</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>January 28, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <disposition_first_submitted>February 16, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 16, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 18, 2011</disposition_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Teniposide</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

